Drug Profile
Thalassaemia gene therapy - Crucell
Latest Information Update: 24 Jun 1998
Price :
$50
*
At a glance
- Originator Crucell
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thalassaemia
Most Recent Events
- 24 Jun 1998 Discontinued-Preclinical for Thalassaemia in Netherlands (Injection)
- 17 Nov 1997 New profile
- 17 Nov 1997 Preclinical development for Thalassaemia in Netherlands (Injection)